Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación
Artículo científico (JournalArticle)
ONECUT2 reprograms neuroendocrine fate and is an actionable therapeutic target in small cell lung cancer
Small cell lung cancer (SCLC) is a highly aggressive malignancy with extremely poor prognosis. SCLC cells exhibit high plasticity and can progress from neuroendocrine (NE) to non-NE phenotypes. This dynamic evolution promotes treatment resistance and relapses, representing a challenge for targeted therapies in this elusive disease. Here we identify the transcription factor ONECUT2 (OC2) as a driver of plasticity in SCLC, leading to non-NE transcriptional states. OC2 is highly expressed in SCLC tumors compared to normal lung tissue and its expression is associated with heightened clinical stage and lymph node metastasis. We show that OC2 is a repressor of ASCL1, the NE master regulator transcription factor. In addition, OC2 upregulates non-NE programs through activation of c-MYC and Notch signaling. We also demonstrate that OC2 is required for growth and survival of SCLC cells and that it can be targeted with a small molecule inhibitor that acts synergistically with the standard combination of cisplatin and etoposide, providing a novel therapeutic strategy for OC2 active SCLC tumors., Open Access funding provided by Universidad Pública de Navarra.
This research was funded by: The Spanish Ministry of Science, Innovation and Universities, grant number: PID2019-109577RA-I00/AEI/10.13039/501100011033 (M.R.); The Spanish Ministry of Science, Innovation and Universities (Ramón y Cajal Program) grant number: RYC-2018-023874-I (M.R.); 2021/22 Predoctoral Fellowship UPNA-RYC program (M.G.); The Spanish Ministry of Science, Innovation and Universities, grant number: FPU22/03658 (I.Z.); Department of Health, Government of Navarre, grant number: 026/2022 (M.R.); Cedars-Sinai Medical Center CTSI grant UL1TR001881 (M.R.F. and M.R.); The Samuel Oschin Comprehensive Cancer Institute (SOCCI) at Cedars-Sinai Medical Center through the 2018 Donna and Jesse Garber Award for Cancer Research (M.R.); 2022 Cancer Biology Program Discovery Fund Award (S.Y. and M.R.F.); The Neuroendocrine Tumor Research Foundation through a 2024 mentored award (N.A. and L.F-C.). The lungNENomics project has been funded by the French Institute National du Cancer, grant number: INCa PRT-K-2017 (L.F-C.); NETRF 2019 Investigator Award (L.F-C.), and Worldwide Cancer Research-2020 Grant Round (L.F-C.). This work has also been supported by FIMA, CIBERONC (CB16/12/00443), Spanish Ministry of Science and Innovation and Fondo de Investigación Sanitaria Fondo Europeo de Desarrollo Regional (PI22/00451), a Lung Ambition Alliance grant (L.M.M.) and ISCIII-Fondo de Investigación Sanitaria-Fondo Europeo de Desarrollo Regional 'Una manera de hacer Europa' (PI22/01253; A.C.).